Truist raised the firm’s price target on Exponent to $100 from $95 and keeps a Buy rating on the shares. The company reported “impressive” Q1 results that reflect the highs that its reactive business can produce and serve as a key proof point of Exponent’s potential, the analyst tells investors in a research note. Truist is also raising its FY24 EPS view on Exponent by 18c to $1.93.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXPO:
- Exponent Announces Quarterly Dividend, Rewards Shareholders
- Exponent sees 2024 revenue before reimbursements up low-single digits
- Exponent Declares Regular Quarterly Dividend for Q2 2024
- Exponent sees Q2 revenue before reimbursements flat to up low-single digits
- Exponent reports Q1 EPS 59c, consensus 47c
